Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In PlaceSeeking Alpha • 06/04/24
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 DataGlobeNewsWire • 06/03/24
Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/20/24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated MilestonesGlobeNewsWire • 05/13/24
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual MeetingGlobeNewsWire • 05/07/24
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual MeetingGlobeNewsWire • 05/01/24
Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)Zacks Investment Research • 04/25/24
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 04/10/24
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/03/24
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to TradeZacks Investment Research • 04/01/24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated MilestonesGlobeNewsWire • 03/26/24
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/27/24
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic ApproachGlobeNewsWire • 02/21/24
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative DiseasesGlobeNewsWire • 01/08/24
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/27/23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common StockGlobeNewsWire • 12/20/23
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary EndpointGlobeNewsWire • 12/20/23
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement PathwayGlobeNewsWire • 12/20/23